Last update Dec. 1, 2004

Zalcitabine

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Anti-HIV drug with frequent and severe side effects. No experience on children younger than 6 mo is available.
Mothers must be adviced that transmission of HIV infection through breastfeeding has been documented.

Alternatives

We do not have alternatives for Zalcitabine.

Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Zalcitabine is also known as


Group

Zalcitabine belongs to this group or family:

Tradenames

Main tradenames from several countries containing Zalcitabine in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 88 %
Molecular weight 211 daltons
Protein Binding 4 %
Tmax 2 hours
T1/2 2 hours

References

We are working to add the scientific references of this product. It will be available soon. If you wish to have access to this information, please let us know by leaving your comment in the opinion section below.

Total visits

2,521

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM